Trial Profile
A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs CYT 001 (Primary) ; Eftilagimod alpha (Primary) ; Poly ICLC (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms CRESCENT 1
- 17 Mar 2023 Results assessing safety of therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma published in the Hepatology Research
- 19 May 2021 Status changed from recruiting to active, no longer recruiting.
- 22 Jun 2020 According to a CYTLIMIC media release, the inclusion of patients will be continued at Yamaguchi University Graduate School of Medicine, until the end of September 2020 or the number of included patients reaches 20.